Login to Your Account



Boston Biomedical cancer drug stumbles in phase III

By Michael Fitzhugh
Staff Writer

Monday, June 26, 2017

Boston Biomedical Inc. unblinded a global phase III study of its cancer stem cell pathway inhibitor, napabucasin, in advanced gastric and gastroesophageal junction cancer after the trial's DSMB determined that combining napabucasin with paclitaxel is unlikely to yield better OS.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription